The needles market refers to the global industry that manufactures and distributes medical needles used for injections, blood collection, surgical procedures, and drug delivery. The market encompasses various types of needles, including safety-engineered, pen, conventional, suture, spinal, and blood collection needles.
The global needles market size was valued at USD 7.32 billion in 2024 and is projected to reach USD 13.12 billion by 2033, growing at a compound annual growth rate (CAGR) of 6.4% between 2025 and 2033. Growth is driven by increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular conditions, rising demand for vaccinations, and expansion of healthcare infrastructure globally. Technological advancements, including safety-engineered and retractable needles, have also contributed to market growth by reducing the risk of needlestick injuries.
Minimally invasive procedures, self-administration of drugs, and global immunization programs have further supported the adoption of needles in both hospital and home care settings.
For a complete analysis, actionable insights, and strategic guidance, purchase the full report here: https://straitsresearch.com/report/needles-market/request-sample
The adoption of safety-engineered and retractable needles has increased due to concerns over needlestick injuries. Regulatory frameworks, such as the U.S. OSHA standards and the EU Council Directive 2010/32/EU, mandate the use of safer needle devices. Companies like Becton, Dickinson and Company (BD) have developed retractable and auto-disable needle systems to improve healthcare worker safety and compliance during vaccination programs.
The rise of biologics and personalized injectable therapies has created demand for fine-gauge, precision-engineered needles. Prefilled syringes, autoinjectors, and ultra-thin pen needles support patient comfort and accurate drug delivery, especially for home-based self-administration.
Chronic Diseases: Increasing rates of diabetes and cancer drive demand for insulin, chemotherapy, and specialized needles.
Vaccination Programs: Global initiatives, including the Global Vaccine Action Plan (GVAP) and campaigns by Gavi, the Vaccine Alliance, increase needle usage worldwide.
Technological Innovation: Advancements in safety features, retractable designs, and eco-friendly materials support growth.
Improper Disposal and Reuse: Inadequate disposal infrastructure, particularly in developing regions, increases the risk of infections such as HIV and hepatitis B and C.
Environmental Concerns: Improper disposal of medical sharps contributes to pollution and regulatory challenges.
North America: Largest market due to advanced healthcare infrastructure, high chronic disease prevalence, and strong regulatory oversight.
Asia-Pacific: Fastest-growing region, supported by large populations, expanding healthcare access, rising chronic disease prevalence, and increasing medical tourism.
Europe: Growth supported by stringent safety regulations, public health initiatives, and adoption of safety-engineered needles under the EU Sharps Directive.
For a complete analysis, actionable insights, and strategic guidance, purchase the full report here: https://straitsresearch.com/report/needles-market/request-sample
By Product Type: Safety needles, conventional needles, pen needles, suture needles, blood collection needles, spinal needles, others.
By Application: Drug delivery, vaccination, blood collection, surgical procedures, others.
By End-User: Hospitals and clinics, ambulatory surgical centers, diagnostic centers, home healthcare settings, others.
By Region: North America, Europe, Asia-Pacific, Middle East and Africa, Latin America.
Major companies in the global needles market include:
Becton, Dickinson and Company (BD)
Johnson & Johnson (Ethicon)
Stryker Corporation
Medtronic PLC
Novo Nordisk A/S
Boston Scientific Corporation
Smiths Medical
Terumo Corporation
Nipro Corporation
Vita Needle Company
BD (May 2024): Launched ultra-fine pen needles to improve patient comfort for insulin administration.
Embecta (July 2024): Considering a potential sale due to declining profits, with advisory support from Centerview Partners.